Alnylam Pharmaceuticals has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Ltd. as part of the strategic alliance the companies formed in May 2008. This payment is related to the achievement of certain pre-defined objectives in the transfer of Alnylam’s platform technology, including documents, materials, and know-how, to Takeda for the development of RNAi therapeutics. Alnylam previously received $120 million in upfront and technology transfer payments fr...